Mirati Therapeutics (NASDAQ:MRTX) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncology Virtual Congress.
The updated cohort enrolled patients who were previously treated with platinum-containing chemotherapy but were checkpoint inhibitor naïve.
As of the data cut-off on July 30, 30 out of 40 patients were evaluable and findings showed:
Objective response rate of 37%, with 1 patient achieving a complete response (CR) and 10 patients achieving a partial response (PR).
22/30 (73%) patients achieved clinical benefit.
Secondary efficacy endpoints continue to mature with a median follow-up of 8.7 months.
On the safety front, sitravatinib and nivolumab combination has been well-tolerated.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.